ESPR vs PH · rev $332.3M vs P/E 28, rev $19.85B
Esperion Therapeutics Inc (ESPR) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
ESPR currently screens at market cap $816.9M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the ESPR and PH stock pages for the full models.
Not investment advice.